“Targeting” hepatitis C after liver transplantation-Reference-Cited by-同舟云学术

“Targeting” hepatitis C after liver transplantation

Published:2015-12-28 Issue:1 Volume:22 Page:9-11
ISSN:1527-6465
Container-title:Liver Transplantation
language:en
Short-container-title:Liver Transpl

Author:

Londoño Maria-Carlota¹,Mariño Zoe¹,Forns Xavier¹

Affiliation:

1. Liver Unit, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Barcelona Spain

Funder

Instituto de Salud Carlos III

Ministerio de Economía y Competitividad

Fondo Europeo de Desarrollo Regional, Unión Europea, Una manera de hacer Europa

Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement

Publisher

Wiley

Subject

Transplantation,Hepatology,Surgery

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/lt.24368/fullpdf

Reference10 articles.

1. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation;Gambato;J Hepatol,2014

2. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study;Lawitz;Lancet,2014

3. EASL recommendations on treatment of hepatitis C 2015;European Association for Study of Liver;J Hepatol,2015

4. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real-world experience from the Hepatitis C Therapeutic Registry and Research Network;Brown;Liver Transpl,2015

5. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients;Gutierrez;Liver Transpl,2015

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Filling the gap between clinical trials and real life in the treatment of severe HCV recurrence after liver transplantation;Transplant International;2017-03